Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables (2016 - 2025)

Historic Receivables for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $147.3 million.

  • Amphastar Pharmaceuticals' Receivables rose 519.37% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.3 million, marking a year-over-year increase of 519.37%. This contributed to the annual value of $136.5 million for FY2024, which is 1874.49% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Receivables stood at $147.3 million for Q3 2025, which was up 519.37% from $133.5 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Receivables registered a high of $147.3 million during Q3 2025, and its lowest value of $67.9 million during Q2 2021.
  • Its 5-year average for Receivables is $107.2 million, with a median of $104.7 million in 2023.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Receivables tumbled by 612.28% in 2022, and later surged by 5393.47% in 2023.
  • Amphastar Pharmaceuticals' Receivables (Quarter) stood at $78.8 million in 2021, then rose by 13.2% to $89.2 million in 2022, then increased by 28.85% to $114.9 million in 2023, then rose by 18.74% to $136.5 million in 2024, then rose by 7.93% to $147.3 million in 2025.
  • Its last three reported values are $147.3 million in Q3 2025, $133.5 million for Q2 2025, and $144.8 million during Q1 2025.